greeksoup/ stock research
Stock research / United States / SNY / Year to 31 December 2019

Sanofi (SNY) annual results, year to 31 December 2019: revenue EUR 36,126 million, from the 20-F

Sanofi files a 20-F with the SEC once a year, in euros. In the year to 31 December 2019 it reported revenue from the sale of goods of EUR 36,126 million ($40.4 billion at the year's average rate), up 4.8% on the year before. Its profit attributable to shareholders was EUR 2,754 million, down 36.0%, and diluted earnings per share EUR 2.23.

Revenue
EUR 36,126 million
+4.8% on the year
FY2015FY2019
Operating margin
8.4%
13.6% a year earlier
FY2015FY2019
Net income
EUR 2,754 million
-36.0% on the year
FY2015FY2019
Diluted EPS
EUR 2.23
-35.0% on the year
FY2015FY2019

this yearthe year beforeIn euros as filed. Hover a bar for its figure.

Income statement (profit and loss)

Year toDec 2018Dec 2019 †
Revenue from the sale of goods34,46336,126
Cost of sales11,43511,979
Gross profit24,24225,652
Research and development5,8946,020
Selling, general and administrative9,8599,884
Operating profit4,6763,051
Finance costs435440
Income tax481121
Profit for the year4,4102,785
Profit attributable to shareholders4,3062,754
Filing20-F20-F
EUR million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed.
Read moreA line the company does not file under the standard tag is left out rather than estimated.
Year toDec 2018Dec 2019 †
Diluted EPS3.432.23
Basic EPS3.452.24
Filing20-F20-F

EUR per ordinary share, as filed.

Cash flow

Year toDec 2018Dec 2019 †
Cash from operations5,5477,715
Cash from investing-12,866-1,183
Cash from financing3,934-4,193
Buybacks1,1019.0
Dividends paid3,7733,834
Filing20-F20-F

EUR million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.

Balance sheet

Year toDec 2018Dec 2019 †
Funded by
Equity attributable to shareholders58,87659,056
Non-controlling interests159174
Borrowings, as filed24,58624,568
Lease liabilitiesn/a1,163
Other liabilities27,78727,669
Total equity and liabilities111,408112,630
Owned
Property, plant and equipment9,6519,717
Goodwill44,23544,519
Other intangible assets21,88916,509
Cash and cash equivalents6,9259,427
Inventories7,4777,994
Other assets21,23124,464
Total assets111,408112,630
Filing20-F20-F

EUR million, at each fiscal year end.

Ratios on the filed lines

Year toDec 2018Dec 2019 †
Return on year-end equity7.3%4.7%
Filing20-F20-F

Arithmetic on the filed lines of the same year.

20-F for the year to 31 December 2019, filed 23 February 2022: the filing. The figures are in euros as filed.